ערך בספרים למניה: atarabio.com (ATRA)

The robotization of bioreactors for human-free T-cell cultivation serves as the primary growth catalyst for Atara Biotherapeutics (ATRA). The book value per share metric visualizes this process, where the value of -3.93 corresponds to the current metric. The creation of an "off-the-shelf" therapy ecosystem opens new horizons in immunology, while stable revenue from European sales ensures the coverage of all operating expenses for Atara Biotherapeutics.

Book value per share determines the portion of net assets attributable to a single instrument, serving as a fundamental floor against excessive price declines. By analyzing the historical book value chart, an investor assesses the actual asset base of Atara Biotherapeutics (ATRA), which is critical given the current reduction of loss-making programs and the company's transition to a strict resource-saving model in conjunction with its pharma partner.